Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Significance of CDH13 Promoter Methylation in Serum Samples from Patients with Bladder Transitional Cell Carcinoma

1 Feb 2011

Abstract excerpt

H-cadherin (CDH13; also known as T-cadherin), which functions as a tumour suppressor, is frequently silenced by promoter methylation in human cancers including bladder transitional cell carcinoma (TCC). This study investigated the clinical significance of methylation of the CDH13 gene promoter in serum from patients with bladder TCC. Methylation status of CDH13 in serum samples from 127 patients with primary...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bladder and Urothelial Cancer Treatments
Share to Epigenetics and DNA Methylation
Share to Urinary and Genital Oncology Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21672320
DOI: 10.1177/147323001103900119

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Significance of CDH13 Promoter Methylation in Serum Samples from Patients with Bladder Transitional Cell CarcinomaPMID 21672320Read ↗

Aberrant Methylation of CDH13 is a Potential Biomarker for Predicting the Recurrence and Progression of Non Muscle Invasive Bladder CancerSemantic proximity Read ↗

Clinical and Prognostic Significance of Protocadherin-10 (PCDH10) Promoter Methylation in Bladder CancerSemantic proximity Read ↗

A Systematic Analysis of the Relationship of CDH13 Promoter Methylation and Breast Cancer Risk and Prognosis.Semantic proximity Read ↗

CDH1 and CDH13 methylation in serum is an independent prognostic marker in cervical cancer patientsSemantic proximity Read ↗

Clinical Relevance of CDH1 and CDH13 DNA-Methylation in Serum of Cervical Cancer PatientsSemantic proximity Read ↗

Gene Expression, DNA Methylation and Prognostic Significance of DNA Repair Genes in Human Bladder CancerSemantic proximity Read ↗

Role of CDH1 promoter polymorphism and DNA methylation in bladder carcinogenesis: a meta-analysis.Semantic proximity Read ↗

Hypermethylation of an E-cadherin (CDH1) promoter region in high grade transitional cell carcinoma of the bladder comprising carcinoma in situ.Semantic proximity Read ↗

Promoter hypermethylation of CDH13 is a common, early event in human esophageal adenocarcinogenesis and correlates with clinical risk factorsSemantic proximity Read ↗

E-cadherin gene promoter hypermethylation may contribute to the risk of bladder cancer among Asian populations.Semantic proximity Read ↗

Characterization of PHGDH expression in bladder cancer: potential targeting therapy with gemcitabine/cisplatin and the contribution of promoter DNA hypomethylationSemantic proximity Read ↗

DNA polymorphisms in exon 1 and promoter of the CDH1 gene and relevant risk of transitional cell carcinoma of the urinary bladder.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.